As s stated by the IFC, the project consists in a US$55 million A loan to Sansure Biotech to improve the Company’s export capacities through: i) construction of an automated manufacturing and R&D facility in Changsha; ii) expansion in Indonesia and Philippines to establish subsidiaries that will be responsible for sales, marketing, product development and technology support in the Southeast Asia region; and iii) setting up representative offices in Africa.
As stated by the IFC, Sansure Biotech Inc. is an in vitro diagnostic solution provider in China and engages in the production and sales of diagnostic reagents and instruments, and the provision of testing and research services. The Company’s headquarter is located at Changsha, Hunan Province, China and has two manufacturing bases and research and development centers in Changsha and Shanghai as well as three clinical laboratories in Changsha, Beijing and Shanghai. The Company has partnered with over 2,000 hospitals and laboratories in China, and its technology has been deployed in over 160 countries.
Sansure’s single largest shareholder is its Founder and Chairman, Dr. Dai Lizhong, who directly and indirectly owns 37.6 percent of the Company. The other shareholders of the Company are employees and public shareholders.
|Private Actor 1||Private Actor 1 Role||Private Actor 1 Sector||Relation||Private Actor 2||Private Actor 2 Role||Private Actor 2 Sector|
|-||-||-||-||Sansure Biotech Inc.||Client||Education and Health|
General IFC Inquiries - IFC Communications:
Address: 2121 Pennsylvania Avenue, NW, Washington DC 20433
Telephone: +1 202-473-3800
Fax: +1 202-974-4384
Client - Sansure Biotech Inc.
ACCESS TO INFORMATION
You can submit a request for information disclosure at: https://disclosures.ifc.org/#/inquiries
If you believe that your request for information from IFC has been unreasonably denied, or that this Policy has been interpreted incorrectly, you can submit a complaint at the link above to IFC's Access to Information Policy Advisor, who reports directly to IFC's Executive Vice President.
ACCOUNTABILITY MECHANISM OF IFC/MIGA
The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at CAO@worldbankgroup.org You can learn more about the CAO and how to file a complaint at http://www.cao-ombudsman.org